Kristina Preuer

dblp:217/2935 · DBLP profile ↗
← Back
1ranked-venue papers
1as first author
0since 2021 · last 2018
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%
Artificial intelligence
1 paper
Deep learning architectures and training · 100%

Topics — the 3 heaviest of 3, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Machine learning › Deep learning architectures and training
feedforward neural network
0.312018
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning · Bioinform. 2018
Bioinformatics and computational biology
drug discovery
0.312018
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning · Bioinform. 2018
Bioinformatics and computational biology › drug discovery › drug combination prediction
drug synergy prediction
0.312018
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning · Bioinform. 2018

Methods — techniques the papers use, named apart from their topics

support vector machine · 0.7random forest · 0.7elastic net · 0.7deep learning · 0.7gradient boosting machines · 0.3gradient boosting machine · 0.3
YearPublicationVenuePosition
2018 DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
abstract
Motivation: While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data. Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance. However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies. Results: DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error. DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines. At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73. Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90. Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset. We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations. Availability and implementation: DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy. Contact: [email protected]. Supplementary information: Supplementary data are available at Bioinformatics online.
Kristina Preuer, Richard Lewis 0002, Sepp Hochreiter, Andreas Bender 0002, Krishna C. Bulusu, Günter Klambauer
Bioinform.1